Business Wire

Cabot Properties Expands European Leadership Team to Capitalize on Increasingly Attractive Logistics Property Market

14.1.2025 18:07:00 CET | Business Wire | Press release

Share

Thomas Schellhorn joins firm as Vice President, Asset Management in Germany; Justin Harvey, Managing Director, Head of UK and Europe, to relocate to London

Cabot Properties, a leading investor, developer and operator of logistics properties throughout the United States, Europe and Asia Pacific, today announced that it has expanded its European leadership team as it continues to grow its presence across the region. The firm has hired Thomas Schellhorn as Vice President to oversee asset management for Cabot’s operations in Germany and the Netherlands. In this role, he will be responsible for leasing and capital improvement programs and will report to Jed Raymond, Senior Director and Head of Asset Management for UK and Europe. Justin Harvey, Managing Director and Head of UK and Europe, will relocate to Cabot’s London office to continue leading the firm’s overall strategy and operations across Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114998320/en/

null

Thomas Schellhorn, Vice President, Asset Management, Germany and The Netherlands (Photo: Business Wire)

“Justin has been an integral member of our team over the last 17 years, contributing to significant growth at Cabot at a key societal inflection point – the growth of the ecommerce sector – which spurred robust demand for high-quality, well-located industrial assets on a global basis,” said Franz Colloredo-Mansfeld, Chairman and CEO of Cabot Properties. “As we recognized the opportunity to expand our investment activity outside the U.S. over a decade ago, he took on the challenging mandate to lead our investment activity and has generated impressive results to date. We’ve since grown our presence in Europe with teams located in the U.K., the Netherlands, and Germany. With Justin in London, the team in Europe is even better positioned to expand our investment activity.”

Cabot has acquired more than 970,000 square meters of logistics properties in Europe and the U.K. since 2011, adding nearly 300,000 square meters to its portfolio in the last two years alone. The company has been active in the German market since 2019 and opened a Munich office in 2024 to support its continued local portfolio growth.

“We see strong opportunity and positive demand tailwinds in the European logistics market, making this a critical moment to expand our team and focus across the region,” said Harvey. “Germany has one of the largest and most important logistics markets in Europe, and Thomas’ depth of knowledge, experience and relationships will give us an excellent advantage for growth in that market. This will help enable our European team to effectively execute a targeted management strategy that we believe will provide long-term value for our investors.”

Schellhorn joins Cabot following four years at Catella Real Estate AG, where he served as a Senior Asset Manager overseeing logistics properties and advising on acquisition and sustainability assessments. His experience in the German logistics real estate space has also spanned several leadership roles at reputable logistics and facility management firms including RLI Investors GmbH, Prologis Germany, DIW Instandhaltung Ltd., and the HOCHTIEF Group. Schellhorn studied facility management at the University of Applied Sciences Kufstein in Austria, graduating as a Qualified Engineer. He is also a Chartered Facility Management Surveyor with the Royal Institution of Chartered Surveyors (RICS).

Harvey has been with Cabot since 2008, having served in various leadership positions throughout the firm’s investment and finance teams prior to taking on his current role in overseeing the firm’s investment activity in Europe. Prior to joining Cabot, Harvey worked at FLAG Capital Management. He holds a Bachelor of Arts from Colby College and a Master of Business Administration from Dartmouth’s Tuck School of Business.

About Cabot Properties

Cabot Properties is an international private equity real estate firm focused on the logistics sector. Founded in 1986, Cabot was one of the first real estate firms to provide institutional investors with access to the industrial property sector and has invested over $15 billion in logistics real estate, served over 4,200 tenants, and operated over 1,600 buildings totaling more than 230 million square feet. Cabot is headquartered in Boston with offices in Atlanta, Chicago, Dallas, Los Angeles, London, Amsterdam, Sydney, Tokyo, and Munich. For more information, visit www.cabotprop.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114998320/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye